What Does an EUS Drug-Device Combination Cost?

Capital equipment, single-use consumables, drug costs, and total ownership for therapeutic endoscopic ultrasound systems — with sourced price data and a note on data limits

---

Budgeting for a therapeutic endoscopic ultrasound (EUS) drug-device combination spans a wide range depending on what you are actually buying: the imaging platform alone, the specialized drug-delivery needle accessories, or the full stack including drug costs. Published and verifiable price data puts the capital equipment range between ~$50,000 and $400,000+, with per-procedure disposable costs adding $200–$700 per case and annual service obligations of $10,000–$30,000+. What moves a facility to one end of that range versus the other is primarily platform generation (traditional dedicated echoendoscope suite vs. add-on transducer architecture), needle design, and the scope of the service agreement. Drug costs — typically ethanol, contrast agents, chemotherapy agents, or biologics delivered under EUS guidance — are budgeted entirely separately and are not reflected in device list prices. MedSource does not yet have aggregate quote data for this category; this article will be updated as facility-level bids accrue.

---

What the Typical Range Is

EUS drug-device combinations are regulated by the FDA as combination products, with the device component generally classified as Class II (subject to 510(k) clearance under 21 CFR Part 876) and the drug component separately governed through CDER or CDRH intercenter review. A combination product is comprised of two or more regulated components — drug/device or biologic/device — that are combined as a single entity, or is a product labeled for use with a specified drug, device, or biologic where both are required to achieve the intended use.

On the capital equipment side, two architectures dominate the market and define the price poles:

• Traditional dedicated EUS suite (Olympus, PENTAX Medical, Fujifilm): Traditional ultrasound scanners cost $200,000+, multiple specialized echoendoscopes at $80,000+ each, and dedicated service costing $10,000+ have all amounted to about $400,000 total, with a significant investment in that first year often totaling more than $250,000.

• Add-on transducer architecture (EndoSound EVS): The $51,300 figure represents the cost of the EVS in total, combining the cost of the three pieces of capital equipment (EVS Scanner, Ultrasound Transducer Module, and Transducer Extension Cable) at $50,800, and adding the cost of one single-use UDK-T at $500.

The average price point for a high-end EUS system ranges from $150,000 to $300,000, while disposable accessories contribute significantly to overall market revenue.

For the drug-delivery needle accessories — the key "device" component in a drug-device combination — a variety of single-use EUS-guided FNA needle devices are available in 19G, 22G, and 25G configurations. Specialized therapeutic needles (e.g., Cook Medical's EchoTip Ultra for celiac plexus neurolysis) carry per-unit list prices; publicly verified per-needle pricing from GPO and distributor sources is not available at press time. Facilities should request itemized pricing for their specific gauge and needle count per case.

---

What Pushes Price Up — Features, Certifications, Support Tier

• Linear vs. radial echoendoscope: The diagnostic radial array echoendoscope provides a 360°, cross-sectional view of the GI tract and is primarily used for screening, while curvilinear echoendoscopes are useful for therapeutic applications such as tissue sample collection, cyst drainage, biopsies of lesions/lymph nodes, and injection for pain management. Linear (curvilinear) scopes required for drug delivery carry a significant premium over radial.

• Advanced imaging features: Premium processors with elastography, contrast harmonic imaging (CHI), and shear wave measurement add cost. The Aplio i800 EUS, developed through a partnership between Olympus and Canon, is positioned as a premium ultrasound system.

• Needle design complexity: Specialized therapeutic needles such as the EchoTip Ultra Celiac Plexus Neurolysis Needle (Cook Medical), a 20G device specifically designed for EUS-guided celiac plexus block and neurolysis, differ from standard EUS needles in having a solid, sharp, conical tip and an array of side holes for radial delivery of agents. Purpose-built drug-delivery configurations command a per-unit premium over standard FNA needles.

• Needle gauge and material: Nitinol construction in 19G and 22G sizes increases flexibility and cost relative to standard stainless steel. Nitinol-tip needles are increasingly specified for pancreatic head and uncinate lesions.

• Full-service contracts: Comprehensive coverage (parts, labor, loaner scope) for a traditional suite runs materially higher than time-and-materials agreements. Manufacturer-quoted service figures are not publicly posted; expect tiered pricing that scales with scope count.

---

What Pushes Price Down — Refurbished, Older Generation, Lease, GPO Contracts

• GPO contracts: Premier, Vizient, and HealthTrust all carry EUS category agreements. GPO pricing on major-brand echoendoscopes and processors is not publicly listed, but documented discounts in the GI endoscopy category typically run 15–30% off list. Request your GPO's current EUS tier before issuing an RFP.

• Alternative system architectures: The EndoSound Vision System (EVS) offers a fully functioning EUS system with capital equipment at significantly lower cost ($50,000) and does not require an annual service contract or the purchase of expensive echoendoscopes.

• Refurbished echoendoscopes: The used GI endoscope market is active, but buyer-beware caveats apply. Independent service organizations (ISOs) offer refurbished linear echoendoscopes; pricing is not standardized. Verify IEC 60601-1 electrical safety compliance and manufacturer repair history before accepting any refurbished scope into a sterile processing workflow.

• Leasing and per-procedure models: Some distributors offer capital equipment on operating leases (36–60 month terms). Per-procedure models, in which consumable cost is bundled into a per-case fee, are emerging for disposable-heavy platforms. These shift CapEx to OpEx but increase long-run cost at higher volumes.

• CMS pass-through reimbursement: The EVS received a Transition Pass Through (TPT) payment code from CMS in July 2024. The TPT code, C1606, provides additional reimbursement for the disposable component of the EVS under the Medicare Hospital OPPS and ASC Payment System. Facilities adopting qualifying platforms should model this offset before comparing net acquisition costs.

---

Hidden Costs — Install, Training, Calibration, Consumables, Service Contracts

• Training: The Olympus training program's online and hands-on curriculum covers the full spectrum of diagnostic EUS and FNA in four to six months, in preparation for a proctorship with an EUS expert. Proctorship and credentialing costs (travel, locum coverage, CME fees) are not included in equipment pricing and are routinely underbudgeted.

• Ongoing consumables: You'll need at least two scope types — linear echoendoscopes and potentially FNA and FNB needles — all of which are single-use per-procedure. At multiple needles per case, consumable costs compound quickly at volume.

• Reprocessing infrastructure: EUS scopes follow similar reprocessing protocols to other scopes. The EVS footprint is smaller than existing EUS systems, and the transducer module has a simplified reprocessing protocol given the absence of a working channel. Traditional echoendoscopes require high-level disinfection (HLD) in compatible automated endoscope reprocessors (AERs); confirm your existing AERs are validated for the scope diameter and length.

• Drug costs (separate line item): The "drug" component in therapeutic EUS — ethanol (celiac plexus neurolysis), contrast agents, gemcitabine, or investigational biologics in tumor injection protocols — is procured through pharmacy, not through device procurement, and must be budgeted separately. Per-procedure drug costs range from <$50 (ethanol) to several thousand dollars (oncology biologics).

• Medicare procedure reimbursement context: EUS procedures, on average, reimburse $864 per Medicare case, compared with $503 per Medicare case for standard EGDs. Model your payback period against actual payer mix, not Medicare rates alone.

---

How to Negotiate — Concrete Tactics

1. Separate capital from consumables in the RFP. Request itemized pricing for the processor, each echoendoscope model, and each needle SKU. Bundled pricing obscures the true per-procedure cost and limits your leverage at contract renewal.

2. Benchmark against CMS published data. The CMS MEARIS device pass-through database (public) documents the manufacturer-submitted cost of hospital-purchased devices. The $51,300 figure for the EVS in total — covering the three capital components ($50,800) plus one single-use UDK-T ($500) — is derived from manufacturer-submitted CMS cost data. Use this as a floor reference for add-on platform negotiations.

3. Request a trade-in credit on existing GI processors or scopes being displaced. Major OEMs routinely offer credits ranging from 5–15% of list; they are rarely offered proactively.

4. Negotiate service contract scope explicitly. Verify whether the contract covers: loaner scope availability (and at what response time), repair turnaround SLA, firmware updates, and scope remanufacturing vs. replacement. Annual service costs of $10,000+ per scope are confirmed in publicly available ASC industry literature.

5. Model GPO vs. direct pricing side by side. In high-volume GI programs, direct-buy agreements with volume commitments sometimes undercut GPO tiers — but GPO contracts carry administration and compliance advantages.

---

When the Price Feels Off — Red Flags

• Capital priced significantly below $50,000 for a full imaging-plus-drug-delivery platform without a clear consumable revenue model. No-cost capital instruments are typically locked to proprietary, high-margin single-use accessories. Calculate the per-procedure consumable cost over your projected case volume before accepting any "free" capital offer.

• Absence of FDA 510(k) clearance documentation for any device component, or inability to produce the combination product's CDRH/OCP designation letter. A small but growing number of devices combined with drugs and biologics — referred to as combination products — are regulated by the FDA center with responsibility over the product's primary mode of action. Sellers who cannot produce their regulatory authorization document are a compliance risk.

• Service contract with no loaner scope provision. A down echoendoscope with no loaner can idle a therapeutic EUS program entirely. If a loaner is not contractually guaranteed within 24–48 hours, treat that as a cost equivalent to lost procedure revenue.

• Needle pricing that does not specify gauge. List price varies meaningfully by gauge (19G > 22G > 25G) and by needle type (FNB vs. FNA). A quote that references only "EUS needle" without SKU specificity cannot be used for budget forecasting.

• No itemization of installation, IFU training, or ROSE (Rapid On-Site Evaluation) support. Several factors affect tissue acquisition outcomes, including the skill level of the endoscopist, the sampling technique used, availability of rapid on-site evaluation (ROSE), and needle gauge or type. ROSE cytotechnologist time is an operational cost that many procurement budgets omit entirely.

---

Sources

1. CMS MEARIS Device Pass-Through Application Database — Publication DEP240228GJT0X (EndoSound EVS cost documentation, 2024). mearis.cms.gov

2. EndoSound, Inc. — "Bringing EUS to Your ASC: A Roadmap to Success" (White Paper, April 2025). endosound.com

3. ASGE Technology Committee — "Devices for Use with EUS," VideoGIE / Gastrointestinal Endoscopy, PMC5990542. pmc.ncbi.nlm.nih.gov

4. FDA CDRH — Special Considerations for 510(k)s: Combination Products. fda.gov

5. Archive Market Research — EUS Products Market: Decade Long Trends and Forecast 2025–2033 (average selling price reference). archivemarketresearch.com

---

This article reflects publicly available price signals as of May 2025. MedSource has not yet collected aggregate facility-level bid data for this product category. Figures will be updated as quote submissions accrue. All prices should be independently verified through your GPO, distributor, and manufacturer prior to budgeting.